Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
THThird Harmonic Bio, Inc. logo

Third Harmonic Bio, Inc. (THRD)

NASDAQ Global Market · Currency in USD
$5.38 ▼ -0.01 (-0.09%)
At close: Aug 19, 4:00 PM ET. Market closed.

Summary

Previous Close
$5.39
Open
$5.38
Day's Range
$5.38 – $5.38
52 Week Range
$3.18 – $16.02
Volume
1,416,403
Avg. Volume
262,783
Market Cap
$242.79M
Beta (5Y Monthly)
2.13
PE Ratio (TTM)
4.94
EPS (TTM)
$1.09
Earnings Date
--
Forward Dividend & Yield
$0.48 (8.92%)
Ex-Dividend Date
Aug 6, 2014
1y Target Est
$16.15

Profile: Third Harmonic Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
31
CEO
Natalie C. Holles

Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders.

Earnings

DateEst.Actual
Aug 14, 2025-$0.22-$0.26Miss
May 8, 2025-$0.26-$0.35Miss
Mar 27, 2025-$0.36-$0.29Beat
Nov 7, 2024-$0.31-$0.33Miss
Aug 8, 2024-$0.29-$0.26Beat
May 15, 2024-$0.33-$0.20Beat

Analyst view

Consensus price target
$16.15 ▲ +200.2%
Range $3.60 – $23.00
Rating: Hold
Buy 20% · Hold 80% · Sell 0%

Get free alerts on THRD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.